Future Highlights? Novel Products With User Fee Goals In The Second Half Of 2009
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
It looks to be a good bet that 2009 will mark a second year of growth in new drug approvals as FDA enters the second half of the year with a robust first-half NME approval tally and a well-stocked pipeline of novel agents with user fee goal dates in the remaining months of the year.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011